Skarlatos S I
Division of Cardiovascular Diseases, National Heart, Lung and Blood Institute, National Institutes of Health (NHLBI), Bethesda, Maryland, USA.
Clin Pharmacol Ther. 2007 Sep;82(3):334-6. doi: 10.1038/sj.clpt.6100289. Epub 2007 Jul 11.
The development of new and novel clinical therapies depends on our ability to translate basic research findings into meaningful clinical applications. These "translational studies" are expensive and complex but necessary if we are to develop new treatments that prevent or treat heart, lung, and blood diseases. This study describes newly created programs at NHLBI (National Heart, Lung, and Blood Institute), which support academic research efforts to translate gene- and cell-based therapies into viable clinical applications.
新型临床疗法的开发取决于我们将基础研究成果转化为有意义的临床应用的能力。这些“转化研究”成本高昂且复杂,但如果我们要开发预防或治疗心脏、肺和血液疾病的新疗法,它们是必不可少的。本研究描述了美国国立心肺血液研究所(NHLBI)新设立的项目,这些项目支持学术研究工作,以将基于基因和细胞的疗法转化为可行的临床应用。